Alnylam Pharmaceuticals Inc
ALNY
Market Cap$20.25B
Close$
$160.69
0.2% upside
Current Fair Value
0.2% upsideUndervalued by 0.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $20.25 Billion |
|---|---|
| Enterprise Value | $18.90 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-2.65 |
| Beta | 0.0 |
| Outstanding Shares | 126,491,778 |
| Avg 30 Day Volume | 618,830 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -60.97 |
|---|---|
| PEG | 98.13 |
| Price to Sales | 10.69 |
| Price to Book Ratio | -80.2 |
| Enterprise Value to Revenue | 9.43 |
| Enterprise Value to EBIT | -107.48 |
| Enterprise Value to Net Income | -57 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | -4.66 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Alnylam Pharmaceuticals Inc
CEO: John Maraganore